Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects.

Die Pharmazie - 1 Apr 2013

Zheng T, Su C H, Zhao J, Zhang X J, Zhang T Y, Zhang L R, Kan Q C, Zhang S J

Abstract excerpt

PURPOSE: To assess the possibility of using CYP2D6 10 +/- CYP3A5*3 as biomarkers to predict the pharmacokinetics of diltiazem and its two metabolites among healthy Chinese subjects. METHODS 41 healthy Chinese were genotyped for CYP3A5 3 and CYP2D6 10, and then received a single oral dose of diltiazem hydrochloride capsules (300 mg). Multiple blood samples were collected over 48 h, and the plasma concentrations of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Asian People

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biotransformation

Share to Calcium Channel Blockers

Share to Cytochrome P-450 CYP2D6

Share to Cytochrome P-450 CYP3A

Share to Half-Life

Source

Identifiers

PMID: 23700791

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects.PMID 23700791Read ↗

Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype.Semantic proximity Read ↗

Cytochrome P450 2D6*10 genotype affects the pharmacokinetics of dimemorfan in healthy Chinese subjects.Semantic proximity Read ↗

Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem.Semantic proximity Read ↗

Effect of cyp2d6*10 allele on the pharmacokinetics of loratadine in chinese subjects.Semantic proximity Read ↗

Effects of 22 novel CYP2D6 variants found in Chinese population on the metabolism of dapoxetine.Semantic proximity Read ↗

Effects of CYP2D6 *10 and *41 Variants in Healthy Chinese Men on the Pharmacokinetics of Dapoxetine.Semantic proximity Read ↗

Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites.Semantic proximity Read ↗

Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 alleleSemantic proximity Read ↗

Significant impacts of CYP3A4*1G and CYP3A5*3 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients.Semantic proximity Read ↗

Pharmacokinetics of nortriptyline and its 10-hydroxy metabolite in Chinese subjects of different CYP2D6 genotypes.Semantic proximity Read ↗

Pharmacokinetics of metoprolol enantiomers in Chinese subjects of major CYP2D6 genotypes.Semantic proximity Read ↗

Effect of the CYP2D6*10 allele on the pharmacokinetics of clomiphene and its active metabolites.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.